# EDGAR Filing Document

**Accession Number:** 0001053691
**File Stem:** 0001437749-26-020692
**Filing Date:** 2026-6
**Character Count:** 15269
**Document Hash:** 38862dd1f82dbff4e4a0898e80471894
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-020692.hdr.sgml**: 20260615

**ACCESSION NUMBER**: 0001437749-26-020692

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260615

**DATE AS OF CHANGE**: 20260615

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CervoMed Inc.
- **CENTRAL INDEX KEY:** 0001053691
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 300645032
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-54715
- **FILM NUMBER:** 261092121

**BUSINESS ADDRESS:**
- **STREET 1:** 20 PARK PLAZA
- **STREET 2:** SUITE 424
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** (617) 744-4400

**MAIL ADDRESS:**
- **STREET 1:** 20 PARK PLAZA
- **STREET 2:** SUITE 424
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Diffusion Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20160115

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RestorGenex Corp
- **DATE OF NAME CHANGE:** 20140307

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stratus Media Group, Inc
- **DATE OF NAME CHANGE:** 20080722
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BOGER JOSHUA S
- **CENTRAL INDEX KEY:** 0001197023

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 130 WAVERLY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**CervoMed Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Joshua S. Boger, Ph.D.**<br>c/o CervoMed Inc.<br>20 Park Plaza, Suite 424<br>Boston MA 02116<br>(617) 744-4400

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/11/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BOGER JOSHUA S** | Name of reporting person<br>**BOGER JOSHUA S** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**2204143.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**2204143.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2204143.00** | Aggregate amount beneficially owned by each reporting person<br>**2204143.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**20.0%** | Percent of class represented by amount in Row (11)<br>**20.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1)  The Reporting Person (together with his affiliates and other attribution parties) holds (i) 216,817 shares of common stock, par value $0.001 per share ("Common Stock"), of CervoMed Inc. (the "Issuer") owned directly by the Reporting Person, (ii) 1,600,117 shares of Common Stock held by The Joshua S. Boger 2021 Trust DTD 12/09/2021 (the "JSB 2021 Trust"), of which the Reporting Person is the sole trustee, (iii) 195,748 shares of Common Stock held by The Amy S. Boger 2021 Trust, of which the Reporting Person is the sole trustee, (iv) 955,414 shares of Common Stock underlying Series B Warrants (as defined in Item 3 below) held by the JSB 2021 Trust, (v) 955,414 shares of Common Stock underlying Series C Warrants (as defined in Item 3 below) held by the JSB 2021 Trust, and (vi) 32,000 shares of Common Stock underlying stock options granted to the Reporting Person for service on the Issuer's board of directors. The Series B Warrants and the Series C Warrants each contain a provision (the "Maximum Ownership Limitation") which precludes exercise of the applicable Warrants to the extent that, following exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the Common Stock outstanding. Accordingly, the securities reported as beneficially owned by the Reporting Person consist of (i) 2,012,682 shares of Common Stock, (ii) 23,541 shares of Common Stock underlying options exercisable within 60 days of June 11, 2026, and (ii) an aggregate of 167,920 shares of Common Stock that may be acquired upon the exercise of Series B Warrants and/or Series C Warrants, as limited by the Maximum Ownership Limitation. The Reporting Person is currently prohibited from exercising the Series B Warrants and/or Series C Warrants to the extent that such exercise would result in its beneficial ownership of more than 2,204,143 shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities held by the ASB 2021 Trust and the JSB 2021 Trust, except as to his pecuniary interest therein (if any), and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 13 or for any other purpose.

(2)  Percentage ownership is based on an aggregate of 11,026,233 shares of Common Stock outstanding based on (i) 9,258,719 shares of Common Stock as of May 6, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 15, 2026, and (ii) 1,767,514 shares of Common Stock issued in the Issuer's private placement completed June 11, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on June 10, 2026.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
CervoMed Inc.

**(c) Address of Issuer's Principal Executive Offices:**
20 PARK PLAZA, SUITE 424, BOSTON, MA, 02116

This Amendment No. 2 (this "Amendment") amends and supplements the statement on Schedule 13D (as amended, the "Schedule 13D") filed by Joshua S. Boger (the "Reporting Person") with the Securities and Exchange Commission ("SEC") on February 9, 2024, as amended February 26, 2024, and relates to the common stock, par value $0.001 per share (the "Common Stock"), of CervoMed Inc., a Delaware corporation (the "Issuer").

This Amendment amends Items 3, 5, 6 and 7 as set forth below. Capitalized terms used and not otherwise defined in this Amendment have the meanings set forth in the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
2. Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

The information set forth in rows 7 through 13 of the cover page to this Schedule 13D is incorporated herein by reference. As of the date of this Schedule 13D, the Reporting Person may be deemed to beneficially own, in the aggregate, 2,204,143 shares of Common Stock, which represents approximately 19.99% of the shares of Common Stock outstanding. The Reporting Person (together with its affiliates and other attribution parties) holds (i) 216,817 shares of Common Stock owned directly by the Reporting Person, (ii) 1,600,117 shares of Common Stock held by the JSB 2021 Trust, (iii) 195,748 shares of Common Stock held by the ASB 2021 Trust, (iv) 955,414 shares of Common Stock underlying Series B Warrants held by the JSB 2021 Trust, (v) 955,414 shares of Common Stock underlying Series C Warrants held by the JSB 2021 Trust, and (vi) 32,000 shares of Common Stock underlying stock options granted to the Reporting Person for service on the Issuer's Board. The Series B Warrants and the Series C Warrants each contain a provision (the "Maximum Ownership Limitation") which precludes exercise of the applicable Warrants to the extent that, following exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the Common Stock outstanding. Accordingly, the securities reported as beneficially owned by the Reporting Person consist of (i) 2,012,682 shares of Common Stock, (ii) 23,541 shares of Common Stock underlying options exercisable within 60 days of June 11, 2026, and (ii) an aggregate of 167,920 shares of Common Stock that may be acquired upon the exercise of Series B Warrants and/or Series C Warrants, as limited by the Maximum Ownership Limitation. The Reporting Person is currently prohibited from exercising the Series B Warrants and/or Series C Warrants to the extent that such exercise would result in its beneficial ownership of more than 2,204,143 shares of Common Stock.

The Reporting Person disclaims beneficial ownership of the securities held by the ASB 2021 Trust and the JSB 2021 Trust, except as to his pecuniary interest therein (if any), and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 13 or for any other purpose.

The foregoing beneficial ownership is based on an aggregate of 11,026,233 shares of Common Stock outstanding based on (i) 9,258,719 shares of Common Stock as of May 6, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2026, and (ii) 1,767,514 shares of Common Stock issued in the Issuer's private placement completed June 11, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on June 10, 2026.

**(b)**
The information set forth in rows 7 through 13 of the cover page to this Schedule 13D is incorporated herein by reference. As of the date of this Schedule 13D, the Reporting Person may be deemed to beneficially own, in the aggregate, 2,204,143 shares of Common Stock, which represents approximately 19.99% of the shares of Common Stock outstanding. The Reporting Person (together with its affiliates and other attribution parties) holds (i) 216,817 shares of Common Stock owned directly by the Reporting Person, (ii) 1,600,117 shares of Common Stock held by the JSB 2021 Trust, (iii) 195,748 shares of Common Stock held by the ASB 2021 Trust, (iv) 955,414 shares of Common Stock underlying Series B Warrants held by the JSB 2021 Trust, (v) 955,414 shares of Common Stock underlying Series C Warrants held by the JSB 2021 Trust, and (vi) 32,000 shares of Common Stock underlying stock options granted to the Reporting Person for service on the Issuer's Board. The Series B Warrants and the Series C Warrants each contain a provision (the "Maximum Ownership Limitation") which precludes exercise of the applicable Warrants to the extent that, following exercise, the holder, together with its affiliates and other attribution parties, would own more than 19.99% of the Common Stock outstanding. Accordingly, the securities reported as beneficially owned by the Reporting Person consist of (i) 2,012,682 shares of Common Stock, (ii) 23,541 shares of Common Stock underlying options exercisable within 60 days of June 11, 2026, and (ii) an aggregate of 167,920 shares of Common Stock that may be acquired upon the exercise of Series B Warrants and/or Series C Warrants, as limited by the Maximum Ownership Limitation. The Reporting Person is currently prohibited from exercising the Series B Warrants and/or Series C Warrants to the extent that such exercise would result in its beneficial ownership of more than 2,204,143 shares of Common Stock.

The Reporting Person disclaims beneficial ownership of the securities held by the ASB 2021 Trust and the JSB 2021 Trust, except as to his pecuniary interest therein (if any), and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 13 or for any other purpose.

The foregoing beneficial ownership is based on an aggregate of 11,026,233 shares of Common Stock outstanding based on (i) 9,258,719 shares of Common Stock as of May 6, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2026, and (ii) 1,767,514 shares of Common Stock issued in the Issuer's private placement completed June 11, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on June 10, 2026.

**(c)**
The response to Item 3 is incorporated by reference herein. The Reporting Person was involved in (i) the Merger as a security holder of EIP, (ii) the Warrant Amendment and subsequent exercise as sole trustee of the JSB 2021 Trust, (iii) the granting of an option pursuant to the Issuer's non-employee director compensation program on June 8, 2026 as a non-employee director of the Issuer, and (iv) the transactions contemplated by the Purchase Agreement as sole trustee of the JSB 2021 Trust. Except as set forth in this Schedule 13D, no transactions in the shares of Common Stock have been effected by the Reporting Person within the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

3. Item 6 of the Schedule 13D is hereby amended and restated in its entirety as follows:

The response to Item 3 relating to the Option Agreement, the Purchase Agreement, the Series B Warrant, and the Series C Warrant is incorporated by reference herein. In addition, in connection with the Purchase Agreement, the Reporting Person entered into a customary lock-up agreement, pursuant to which the Reporting Person has agreed not to, except in limited circumstances, transfer, grant an option with respect to, sell, exchange, pledge or otherwise dispose of, or encumber any shares of the Common Stock for a period of time following the Private Placement.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BOGER JOSHUA S

**Signature:** /s/ William R. Elder

**Name/Title:** William R. Elder, Attorney-in-Fact for the Reporting Person

**Date:** 06/15/2026